Beijing, China – 16 Sep 2026 – China’s National Medical Products Administration (NMPA) and the General Administration of Customs of China (GACC) jointly announced the launch of an electronic customs clearance pilot program for imported drugs (including medicinal crude materials) at Beijing Port, effective from the date of announcement. Under the pilot, electronic clearance documents carry the same legal force as their paper counterparts, marking a milestone in the digitization of China’s pharmaceutical import supervision.
Policy Snapshot
| Item | Detail |
|---|---|
| Issuing Agencies | NMPA and General Administration of Customs of China (GACC) |
| Policy Type | Pilot program for electronic customs clearance documentation |
| Scope | Imported drugs, including medicinal crude materials (药材) |
| Pilot Location | Beijing Port |
| Effective Date | 16 Sep 2026 (from date of announcement) |
| Legal Status | Electronic clearance documents have equal legal force with paper documents |
| Transition Arrangement | Paper documents remain valid during the pilot; enterprises may continue using them per existing regulations |
| Expansion Timeline | Not disclosed |
Policy Details & Legal Framework
- Objective: Further advance the digitalization of government services and improve the efficiency and convenience of customs clearance for imported drugs and medicinal materials.
- Legal Parity: For the first time at the pilot port, electronic clearance documents are granted the same legal validity as paper documents — a critical enabler for fully digital cross-border pharmaceutical trade workflows.
- Dual‑Track Transition: During the pilot period, the existing paper documentation remains valid, allowing importers to adopt the electronic channel at their own pace without operational disruption.
- Joint Governance: The announcement was co‑issued by the drug regulator (NMPA) and the customs authority (GACC), reflecting cross‑agency coordination between product regulation and border control in pharmaceutical imports.
Industry Context
- Legacy Paper Burden: Pharmaceutical imports into China have traditionally required paper‑based clearance certificates at ports of entry, adding administrative steps and courier logistics to time‑sensitive shipments.
- Digital Trade Facilitation: The pilot aligns with China’s broader push to digitize government services and cross‑border trade documentation, including electronic customs declaration and paperless clearance reforms.
- Inclusive Scope: By explicitly covering medicinal crude materials (药材) alongside finished drugs, the pilot addresses a segment historically subject to specialized port inspection requirements.
- Strategic Entry Point: Beijing Port — served by Capital International Airport and Daxing International Airport cargo facilities — is a key gateway for imported pharmaceuticals, biologics, and temperature‑sensitive products.
Market Impact & Outlook
- For Importers: Multinational pharmaceutical companies, distributors, and trading firms importing finished drugs, APIs, and herbal materials through Beijing can expect streamlined clearance procedures and reduced paperwork, lowering administrative costs.
- Supply Chain Resilience: Electronic documentation reduces dependence on physical transport of clearance certificates, benefiting cold‑chain and urgent humanitarian shipments.
- Regulatory Signal: The pilot may serve as a template for broader rollout to other major ports should it prove successful; no expansion timeline or additional ports have been disclosed.
- Compliance Note: Enterprises operating dual‑track documentation should ensure internal systems can reconcile electronic and paper records during the transition period.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory implementation timelines, pilot expansion, and operational expectations for electronic customs clearance of imported drugs in China. Actual outcomes may differ due to factors including administrative execution at port level, enterprise adoption rates, and subsequent policy adjustments by the NMPA and GACC..-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260921091608111.html